Cargando…

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy

SIMPLE SUMMARY: This study aimed to identify genes associated with neoadjuvant chemotherapy (NAC) response and disease-free survival (DFS) of triple-negative breast cancer (TNBC) patients. We conducted a large-scale meta-analysis of gene expression data from multiple TNBC cohorts and analyzed four g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Wei, Li, Emma, Wang, Lily, Lehmann, Brian D., Chen, X. Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137141/ https://www.ncbi.nlm.nih.gov/pubmed/37190123 http://dx.doi.org/10.3390/cancers15082194

Ejemplares similares

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

NMR-Based Metabolomics Analysis Predicts Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: He, Xiangming, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis
por: Li, Yunhai, et al.
Publicado: (2019)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional Validation
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2022)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
por: Bao, Jean, et al.
Publicado: (2015)

A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Zheng, Tianzhi, et al.
Publicado: (2019)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review
por: van den Ende, Nadine S., et al.
Publicado: (2023)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
por: Asano, Yuka, et al.
Publicado: (2018)

Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
por: Fisher, Timothy B., et al.
Publicado: (2023)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
por: Feng, Wuna, et al.
Publicado: (2021)

Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer?
por: Atkins, Jordan J., et al.
Publicado: (2013)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response
por: Mohammed, Amrallah A, et al.
Publicado: (2020)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy
por: Hu, Taobo, et al.
Publicado: (2022)

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
por: Vidra, Radu, et al.
Publicado: (2022)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5vim1akd6tlq46089l031c9hpm